Financial Performance - In 2024, the Group achieved operating revenue of RMB 9.855 billion, representing a year-on-year decrease of 2.5%[20] - The net profit attributable to the parent amounted to RMB 566 million, reflecting a year-on-year increase of 119.6%[20] - In 2024, the consolidated revenue of China Resources Medical amounted to RMB 9.855 billion, a decrease from RMB 10.108 billion in FY2023, while the consolidated net profit increased to RMB 672 million from RMB 328 million in FY2023[37] - The Group's net profit for the reporting period was RMB 672 million, representing a year-on-year increase of 104.9%[72] - The revenue from the hospital business segment for 2024 was RMB 9,185 million, representing a year-on-year decrease of 2.4%[55] - Revenue from other business was RMB 670 million, a year-on-year decrease of 4.5%, mainly due to restructuring of supply chain services[57] - The profit of the hospital business segment recorded RMB 766 million, representing a year-on-year increase of 20.1%[56] Operational Metrics - The number of conventional out-patient visits increased to 10.32 million, a year-on-year growth of 1.9%[20] - The number of in-patient visits rose to 0.56 million, representing a year-on-year increase of 1.0%[20] - The number of outpatient visits and inpatient visits for the Group's self-owned hospitals increased by 1.3% and 1.0% year-on-year, respectively, with approximately 10.32 million outpatient visits and 560,000 inpatient visits recorded[36][38] - Out-patient visits increased by 1.3% to 10,325,639, while in-patient visits increased by 1.0% to 560,149[55] Dividends and Shareholder Returns - The Group proposed a dividend of RMB 0.132 per share for 2024, with an interim dividend of RMB 0.05 already distributed and a final dividend of RMB 0.082 proposed[20] - The proposed final dividend for FY2024 is RMB8.2 cents per share, an increase from RMB6 cents per share in FY2023[142] - The total amount of dividend for FY2024 is approximately RMB171 million, with RMB65 million paid as interim dividend and RMB106 million proposed as final dividend[142] - The Group's ability to pay dividends depends on its financial condition, current and future operations, liquidity position, and capital requirements[147] Strategic Focus and Future Plans - The Group aims to deepen structural reforms and improve quality and efficiency in 2025, focusing on core competencies such as discipline construction and digital intelligence[26][30] - The Group aims to strengthen its core competencies in 2025, focusing on discipline construction, patient services, and digital intelligence[105] - The year 2025 marks the conclusion of the "14th Five-Year Plan" and the planning phase for the "15th Five-Year Plan," with a focus on improving quality and efficiency[106] - The Group plans to leverage its state-owned enterprise status to achieve high-quality development and fulfill social responsibilities while enhancing market value management[29][30] Employee and Operational Management - As of December 31, 2024, the Group had a total of 19,953 full-time employees, a decrease from 20,172 employees as of December 31, 2023[95] - For FY2024, the staff cost was approximately RMB 3,470 million, compared to RMB 3,406 million in FY2023, reflecting an increase of about 1.9%[95] - The Group emphasizes the importance of employee safety and development, implementing high standards of health and safety measures[139] Compliance and Governance - The Group has complied with all relevant PRC laws and regulations regarding environmental protection during the year ended December 31, 2024[123] - The Group has established a Supplier Code of Conduct to ensure compliance with local regulations governing labor, health, safety, and the environment[138] - All independent non-executive Directors confirmed their independence and compliance with the Listing Rules during the reporting period[190][193] Investments and Acquisitions - The Group did not have any significant acquisitions or disposals during the reporting period, except for investments in associates[58] - As of December 31, 2024, the Group's investment in JR Holdings and JR Renkang amounted to RMB 874 million and RMB 2.45 million, respectively[63] - JR Holdings and JR Renkang achieved a combined revenue of RMB 373 million, resulting in a net profit of RMB 200 million during the reporting period[64] Customer and Supplier Relations - The Group's five largest customers accounted for approximately 5.1% of total sales in 2024, down from 6.5% in 2023, with the largest customer contributing about 1.5% of total sales, down from 3.0%[168][173] - Purchases from the Group's five largest suppliers represented approximately 12.1% of total purchases in 2024, a decrease from 15.7% in 2023, with the largest supplier accounting for about 2.8% of total purchases, down from 4.6%[169][173]
华润医疗(01515) - 2024 - 年度财报